# MultiSensor AI Holdings, Inc.: overview

MSAI · Nasdaq · CIK 1863990 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/msai.md) · [Financials](/companies/msai/financials.md) · [Filings](/companies/msai/filings.md) · [Insiders](/companies/msai/insiders.md)

Latest reported revenue: [$1.7m](/filings/0001104659-26-095907.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 13, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001104659-26-095907).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1.6](/filings/0001104659-25-111303.md) | [1.4 d](/filings/0001104659-26-032148.md) | [1.2](/filings/0001104659-26-060325.md) | [1.4](/filings/0001104659-26-095907.md) | [1.6](/filings/0001104659-25-111303.md) | [1.4 d](/filings/0001104659-26-032148.md) | [1.6](/filings/0001104659-26-060325.md) | [1.7](/filings/0001104659-26-095907.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(541.5%)](/filings/0001104659-25-111303.md) | [(199.6%) d](/filings/0001104659-26-032148.md) | [(394.6%)](/filings/0001104659-26-060325.md) | [(233.8%)](/filings/0001104659-26-095907.md) | [(107.6%)](/filings/0001104659-25-111303.md) | [(171.6%) d](/filings/0001104659-26-032148.md) | [(160.7%)](/filings/0001104659-26-060325.md) | [(153.5%)](/filings/0001104659-26-095907.md) |
| Net margin | % | [(511.5%)](/filings/0001104659-25-111303.md) | [(213.2%) d](/filings/0001104659-26-032148.md) | [(379.1%)](/filings/0001104659-26-095907.md) | [(234.1%)](/filings/0001104659-26-095907.md) | [(106.5%)](/filings/0001104659-25-111303.md) | [(164.1%) d](/filings/0001104659-26-032148.md) | [(153.1%)](/filings/0001104659-26-095907.md) | [(145.1%)](/filings/0001104659-26-095907.md) |
| Diluted EPS | $ per share | [(0.34)](/filings/0001104659-25-111303.md) | not reported | [(5.42)](/filings/0001104659-26-060325.md) | [(3.96)](/filings/0001104659-26-095907.md) | [(0.05)](/filings/0001104659-25-111303.md) | not reported | [(1.23)](/filings/0001104659-26-060325.md) | [(1.19)](/filings/0001104659-26-095907.md) |
| Free cash flow | $m | [(13.2) d](/filings/0001104659-25-111303.md) | [(4.1) d](/filings/0001104659-26-032148.md) | [(3.6)](/filings/0001104659-26-060325.md) | [(1.3) d](/filings/0001104659-26-095907.md) | [(2.1) d](/filings/0001104659-25-111303.md) | [(2.6) d](/filings/0001104659-26-032148.md) | [(1.8)](/filings/0001104659-26-060325.md) | [(2.6) d](/filings/0001104659-26-095907.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: |
| Revenue | $m | [7.3](/filings/0001410578-24-000361.md) | [5.4](/filings/0001558370-25-004015.md) | [7.4](/filings/0001104659-26-032148.md) | [5.6](/filings/0001104659-26-032148.md) |
| Gross margin | % | not reported | not reported | not reported | not reported |
| Operating margin | % | [(165.4%)](/filings/0001410578-24-000361.md) | [(395.5%)](/filings/0001558370-25-004015.md) | [(255.1%)](/filings/0001104659-26-032148.md) | [(216.4%)](/filings/0001104659-26-032148.md) |
| Net margin | % | [(182.9%)](/filings/0001410578-24-000361.md) | [(410.1%)](/filings/0001558370-25-004015.md) | [(290.4%)](/filings/0001104659-26-032148.md) | [(211.0%)](/filings/0001104659-26-032148.md) |
| Diluted EPS | $ per share | [(2.51)](/filings/0001410578-24-000361.md) | [(3.56)](/filings/0001558370-25-004015.md) | [(1.07)](/filings/0001104659-26-032148.md) | [(0.31)](/filings/0001104659-26-032148.md) |
| Free cash flow | $m | [(4.8)](/filings/0001410578-24-000361.md) | [(6.1)](/filings/0001558370-25-004015.md) | [(18.2)](/filings/0001104659-26-032148.md) | [(9.7)](/filings/0001104659-26-032148.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/msai/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [325 CAPITAL LLC](/funds/1873893.md) | 2026-06-30 | $3.5m | 662,244 |  | New +662,244 |
| [BOOTHBAY FUND MANAGEMENT, LLC](/funds/1549230.md) | 2026-06-30 | $521.0k | 100,000 |  | Unchanged |
| [Bleichroeder LP](/funds/1781002.md) | 2026-06-30 | $159.2k | 30,562 |  | New +30,562 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $112.7k | 21,622 |  | New +21,622 |
| [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $30.6k | 5,870 |  | New +5,870 |
| [Tower Research Capital LLC (TRC)](/funds/1533421.md) | 2026-06-30 | $9.1k | 1,756 |  | New +1,756 |
| [BARCLAYS PLC](/funds/312069.md) | 2026-06-30 | $9.1k | 1,751 |  | New +1,751 |
| [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $6.9k | 1,316 |  | New +1,316 |
| [GOLDMAN SACHS GROUP INC](/funds/886982.md) | 2026-06-30 | $5.9k | 201,766 |  | Unchanged |
| [MMCAP International Inc. SPC](/funds/1304857.md) | 2026-06-30 | $5.1k | 175,250 |  | Unchanged |

## Recent filings

[All 375 filings](/companies/msai/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-13 | 20:07 ET | [10-Q](/filings/0001104659-26-095907.md) | Quarterly report, period 2026-06-30 | 0001104659-26-095907 |
| 2026-08-13 | 20:06 ET | [8-K](/filings/0001104659-26-095901.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-26-095901 |
| 2026-07-20 | 20:05 ET | [8-K](/filings/0001104659-26-085058.md) | 3.02 Unregistered sale of equity; 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001104659-26-085058 |
| 2026-06-18 | 20:05 ET | [8-K](/filings/0001104659-26-075719.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001104659-26-075719 |
| 2026-05-13 | 20:46 ET | [10-Q](/filings/0001104659-26-060325.md) | Quarterly report, period 2026-03-31 | 0001104659-26-060325 |
| 2026-05-13 | 20:38 ET | [8-K](/filings/0001104659-26-060310.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-060310 |
| 2026-04-29 | 21:36 ET | [8-K](/filings/0001104659-26-050512.md) | 8.01 Other events | 0001104659-26-050512 |
| 2026-04-24 | 20:58 ET | [DEF 14A](/filings/0001104659-26-048679.md) | Proxy statement, period 2026-06-12 | 0001104659-26-048679 |
| 2026-04-21 | 20:06 ET | [8-K](/filings/0001104659-26-045999.md) | 3.02 Unregistered sale of equity | 0001104659-26-045999 |
| 2026-03-19 | 21:15 ET | [8-K](/filings/0001104659-26-032178.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-032178 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001104659-26-032148.md), filed Mar 19, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/8added67-172c-48a0-9085-3fa0de217487)

## About the filer

- CIK: 1863990
- Tickers: MSAI, MSAIW
- Exchange: Nasdaq
- SIC code: 3827 Optical Instruments & Lenses
- State of incorporation: DE
- Filer category: Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.